![Francis Sarena](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Francis Sarena
Operationeel Directeur bij Apexigen America, Inc.
Profiel
Francis Willard Sarena is currently the Chief Operating Officer at Apexigen America, Inc. He previously worked as the Chief Strategy Officer at Five Prime Therapeutics, Inc. from 2016 to 2021, and as the Secretary, Vice President & General Counsel at Abbott Biotherapeutics Corp.
from 2008 to 2010.
He also worked as an Associate at BMC Partners LLP from 2000 to 2006.
Mr. Sarena's education includes an undergraduate degree from San Francisco State University in 1996 and a graduate degree from the University of California, Berkeley in 2000.
Actieve functies van Francis Sarena
Bedrijven | Functie | Begin |
---|---|---|
Apexigen America, Inc.
![]() Apexigen America, Inc. Pharmaceuticals: MajorHealth Technology Apexigen America, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its product portfolio includes humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA. | Operationeel Directeur | 04-01-2022 |
Eerdere bekende functies van Francis Sarena
Bedrijven | Functie | Einde |
---|---|---|
APEXIGEN, INC. | President | 23-08-2023 |
FIVE PRIME THERAPEUTICS, INC. | Algemeen Adviseur | 01-09-2016 |
Abbott Biotherapeutics Corp.
![]() Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | Algemeen Adviseur | 01-07-2010 |
PDL BIOPHARMA, INC. | Algemeen Adviseur | 01-12-2008 |
BMC Partners LLP
![]() BMC Partners LLP Miscellaneous Commercial ServicesCommercial Services BMC Partners LLP provides litigation, corporate, finance, restructuring, employment and benefits, and intellectual property services in all industries. It also offers consulting and advisory services in government, investment management, and mergers and acquisitions. The company was founded on July 1, 2002 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01-04-2006 |
Opleiding van Francis Sarena
University of California, Berkeley | Graduate Degree |
San Francisco State University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
APEXIGEN, INC. | Health Technology |
Bedrijven in privébezit | 6 |
---|---|
McCutchen, Doyle, Brown & Enersen LLP
![]() McCutchen, Doyle, Brown & Enersen LLP Miscellaneous Commercial ServicesCommercial Services McCutchen, Doyle, Brown & Enersen LLP provides legal services. The company is based in San Francisco, CA. McCutchen, Doyle, Brown & Enersen was acquired by Bingham Dana LLP on July 01, 2002. | Commercial Services |
PDL BioPharma, Inc.
![]() PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
BMC Partners LLP
![]() BMC Partners LLP Miscellaneous Commercial ServicesCommercial Services BMC Partners LLP provides litigation, corporate, finance, restructuring, employment and benefits, and intellectual property services in all industries. It also offers consulting and advisory services in government, investment management, and mergers and acquisitions. The company was founded on July 1, 2002 and is headquartered in Boston, MA. | Commercial Services |
Five Prime Therapeutics, Inc.
![]() Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
Abbott Biotherapeutics Corp.
![]() Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | Health Technology |
Apexigen America, Inc.
![]() Apexigen America, Inc. Pharmaceuticals: MajorHealth Technology Apexigen America, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its product portfolio includes humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA. | Health Technology |